IOL Chemicals & Pharmaceuticals Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/c3gt844ru7j39tc10cfu3whp.pdf

Key Takeaways


Quarterly Performance & Profitability Drivers

Singh: "The change what has been in this quarter is the uptick in the prices and because we were having all volume, so little bit uptick in prices resulting into those numbers. But inventory, I don't think that we were having any meaningful inventory gain in that quarter because the uptick, I think, was in later part of the quarter."

Ibuprofen: Stabilisation & Outlook

Singh: "No, not at all. I don't know what they are feeling or their concerns are. But regarding the IOL, this is one of the best product, and that is witnessed by the capacity utilizations we are doing now and for last few quarters."

Non-Ibuprofen Pharma & Product Pipeline


Chemical Business & Integration


Greenfield Expansion & Capital Allocation

Singh: "If we start buying back, then growth will be impacted. you know that we also come up with another land of 100 acres. we also need to invest therein. So the funds majorly will be utilized for the enhancing the growth, we have many growth projects. So till the time we have growth projects, I think buyback perhaps may be the second option."

Raw Material, Supply Chain & External Risks

Singh: "it will be better if we gauge the company's performance on the yearly basis rather than the quarterly basis because so much dynamism is happening across the globe. So this is risky to comment on coming quarter or next quarter."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth15% top-line growth (may be 1–2% more or less); targeting ~₹2,700 croresFY27
EBITDA margin14% to 14.5% on annual termsFY27
Ibuprofen demandCurrent stabilised demand level to sustainNext 4–6 quarters
Paracetamol capacity utilisationRise from 55% to 70–75%FY27
Paracetamol full utilisationFull capacity utilisationFY28
Non-Ibuprofen exports to regulated markets~25% export shareFY27
Greenfield approvalsMost approvals secured, work beginsNext 3–4 months
Greenfield project completionAll projects phased inNext 4–5 years
Greenfield annual capex₹200–₹250 crores per year; total ₹1,200–₹1,400 crores, internally fundedOver project life
Employee expense~9–10% of revenueOngoing

Key Metrics

MetricQ4 FY26
Revenue from operations₹619 cr, +17.4% YoY
Full-year revenue FY26₹2,319 cr, +11.5% YoY
EBITDA₹94 cr, +40% YoY
EBITDA margin15.2%, improved 251 bps YoY
Full-year EBITDA margin FY2612.4%, vs 10.7% in FY25
Profit after tax₹53 cr, +68% YoY
PAT margin8.6%, improved 262 bps YoY
Full-year PAT FY26₹138 cr, +36% YoY
FY27 revenue growth guidance~15% (mid to high teens)
FY27 EBITDA margin guidance14% to 14.5%
Capex incurred FY26~₹160 cr, funded entirely through internal accruals
Greenfield total outlay₹1,200 cr to ₹1,400 cr, over 4–5 years
Ibuprofen share of pharma revenue62% this quarter
Non-ibuprofen share of pharma revenue38% this quarter
Ibuprofen capacity utilisation90% to 95%
Paracetamol capacity utilisation55% of enhanced 10,800 MT capacity
Chemical segment capacity utilisation98% to 100% (acetic anhydride and ethyl acetate)
Non-ibuprofen exports target FY27~25% of non-ibuprofen revenue
R&D spend2% to 3% of revenue annually
Inventory₹371 cr
Employee benefit expenses9% to 10% of revenue